5 completed, 1 not yet recruiting. 2 Not applicable, 2 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Completed 2 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
| Phase 3 | 2 | Completed 2 |
Follow Low Bone Mass: new trials by email Literature Review of Low Bone Mass trials Research Report on Low Bone Mass
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass Denosumab, Placebo - Postmenopausal Osteoporosis, Low Bone Mass | Phase 2 | Not yet recruiting | Transcenta Therapeutics (Hangzhou) Co., Ltd. | 110 | 2026-10-31 | 2026-09-11 |
| Resveratrol for the Prevention of Bone Loss in Postmenopausal Women Resveratrol, Placebo - Low Bone Mass | Not applicable | Completed | University of Delaware | 52 | 2024-02-02 | 2026-05-13 |
| DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women DHEA, Placebo, Exercise - Low Bone Mass, Osteoporosis, Postmenopausal | Not applicable | Completed | University of Colorado, Denver | 152 | 2018-02-12 | 2024-12-05 |
| Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis 60 mg denosumab, Placebo - Low Bone Mass, Low Bone Mineral Density | Phase 3 | Completed | Amgen | 242 | 2009-10-01 | 2018-10-17 |
| A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab high-resolution peripheral quantitative computed tomography (HR-pQCT), Dual energy X-ray absorptiometry (DXA), Denosumab - Low Bone Mass, Low Bone Mineral Density | Phase 3 | Completed | Amgen | 79 | 2009-07-01 | 2014-04-02 |
| A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab Previous denosumab - Low Bone Mass, Low Bone Mineral Density | Phase 2 | Completed | Amgen | 15 | 2009-06-01 | 2013-11-15 |
Osteoporosis, Postmenopausal (4) · Bone Diseases, Metabolic (3) · Osteoporosis (3) · Motor Activity (1) · Multiple Endocrine Neoplasia Type 1 (1) · Sclerosteosis (1)
Bone Diseases (5) · Metabolic Diseases (5) · Musculoskeletal Diseases (5) · Nutritional and Metabolic Diseases (5) · Bone Diseases, Metabolic (2) · Osteoporosis (2) · Behavior (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Genetic Diseases, Inborn (1) · Multiple Endocrine Neoplasia (1) · Neoplasms (1) · Neoplasms by Site (1) · Neoplasms, Multiple Primary (1)
Denosumab (3) · Absorptiometry, Photon (1) · Dehydroepiandrosterone (1) · Exercise (1) · Resveratrol (1)
Amgen (3) · Transcenta Therapeutics (Hangzhou) Co., Ltd. (1) · University of Colorado, Denver (1) · University of Delaware (1)
United States (2)
Catherine Jankowski, PhD (1) · Sheau Ching Chai, PhD, RD (1)
R01AG053489 (1), U54GM104941 (1)